<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774916</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00893-40</org_study_id>
    <secondary_id>2012-26</secondary_id>
    <nct_id>NCT01774916</nct_id>
  </id_info>
  <brief_title>Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations</brief_title>
  <official_title>Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cutaneous Arteriovenous malformations (AVM's) rare congenital high-flow vascular&#xD;
      malformations in which arteries and veins are directly connected through a complex web of&#xD;
      abnormal arteries and veins instead of a normal capillary network. Arterial feeders and&#xD;
      enlarged draining veins directly connect through arteriovenous fistulas that create the&#xD;
      &quot;nidus&quot;. The natural history of AVMs is organized into a clinical staging system: during the&#xD;
      first phase of quiescence, the arteriovenous malformation mimics a capillary malformation.&#xD;
      After many years, the AVM may enlarge with loco-regional expansion and tissular destruction.&#xD;
      At the ultimate stage, AVM may impact the heart function. They are considered non malignant&#xD;
      but can expand and become a significant clinical risk when extensive. The management of these&#xD;
      high flow AVM remains often problematic. Complete and large surgical excision of the nidus&#xD;
      after hyperselective embolization is the only potential therapeutic solution but this, is&#xD;
      often difficult if not impossible. There is no pathogenetic hypothesis for the development of&#xD;
      these malformations. Histopathological examination (performed only on surgical resection&#xD;
      specimen) is poor and does not provide sufficient evidence to assess the evolutivity or the&#xD;
      severity of the MAV. Recent data hypothesize that these vascular malformations are associated&#xD;
      with alterations of the vascular endothelium caused by genetic abnormalities involved in the&#xD;
      control of angiogenesis and vascular homeostasis. The detection of these anomalies allows the&#xD;
      search for cellular and genetic markers that might be useful to optimize the clinical&#xD;
      classification, staging, predicting the evolution of these defects and some understanding of&#xD;
      its pathophysiological mechanisms. To our knowledge, no studies to identify cellular markers&#xD;
      / genetic and endothelial associated with the development of cutaneous AVMs have been&#xD;
      published to date.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The exploration of the microparticles, endothelial cells and progenitor cells</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>investigate the relationship between endothelial markers and genetic and clinical characteristics of the disease</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cutaneous Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>volunter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <arm_group_label>patients</arm_group_label>
    <arm_group_label>volunter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or feminine Subject&#xD;
&#xD;
          -  Subject of 10 and more years old,&#xD;
&#xD;
          -  Subject weighing more than 55 kg. patients:&#xD;
&#xD;
          -  Subject presenting a cutaneous artério-venous deformation there outside of any other&#xD;
             deformation or known vascular tumor.&#xD;
&#xD;
          -  Subject presenting no other susceptible pathology to influence endothéliaux markers&#xD;
             (Renal insufficiency, inflammatory pathology chronicles, infections, pathologies&#xD;
             cardiovascular, diabetes, evolutionary tumoral pathology).&#xD;
&#xD;
        volunteers:&#xD;
&#xD;
          -  Unhurt Subject of deformation or vascular tumor.&#xD;
&#xD;
          -  Subject presenting no other susceptible pathology to influence endothéliaux&#xD;
             markers(scorers) (Renal insufficiency, inflammatory pathology chronicles, infections,&#xD;
             pathologies cardiovascular).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject of less than 10 years old&#xD;
&#xD;
          -  Subject weighing less than 55 kg&#xD;
&#xD;
          -  Subject presenting another type(chap) of vascular vascular deformation or tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>michele DAMON</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Degardin</last_name>
    <email>nathalie.degardin@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nathalie degardin</last_name>
      <email>nathalie.degardin@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

